AC   CVCL_8886
DR   CLO; CLO_0007120
DR   ECACC; 95041223
DR   GEO; GSM600370
DR   GEO; GSM830111
DR   Wikidata; Q54900482
RX   PubMed=17242179;
RX   PubMed=19295186;
RX   PubMed=21544390;
RX   PubMed=22538498;
RX   PubMed=23119007;
RX   PubMed=29444910;
RX   PubMed=31548718;
RX   PubMed=31548719;
CC   Problematic cell line: Misclassified. Originally thought to arise from a multifocal carcinoid of the small intestine but shown to be an EBV-transformed lymphoblastoid cell line (PubMed=29444910; PubMed=31548718). Although misidentified, it has been argued that transcriptional regulation of the cells enough resemble gastroenteropancreatic neuroendocrine tumors to be used in studies (PubMed=31548719).
CC   Population: Caucasian.
CC   Doubling time: 1.8 days (PubMed=21544390).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ECACC; 95041223; probable.
CC   Derived from site: In situ; Small intestine, ileum; UBERON=UBERON_0002116.
ST   Source(s): PubMed=29444910
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D21S11: 28,29
ST   D5S818: 11
ST   D7S820: 10
ST   TH01: 7,9
ST   TPOX: 10
ST   vWA: 18,19
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   75Y
CA   Transformed cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 16
RX   PubMed=17242179; DOI=10.1677/jme.1.02037;
RA   Kidd M., Eick G.N., Modlin I.M., Pfragner R., Champaneria M.C.,
RA   Murren J.R.;
RT   "Further delineation of the continuous human neoplastic
RT   enterochromaffin cell line, KRJ-I, and the inhibitory effects of
RT   lanreotide and rapamycin.";
RL   J. Mol. Endocrinol. 38:181-192(2007).
RX   PubMed=19295186; DOI=10.1159/000209330;
RA   Siddique Z.-L., Drozdov I., Floch J., Gustafsson B.I., Stunes K.,
RA   Pfragner R., Kidd M., Modlin I.M.;
RT   "KRJ-I and BON cell lines: defining an appropriate enterochromaffin
RT   cell neuroendocrine tumor model.";
RL   Neuroendocrinology 89:458-470(2009).
RX   PubMed=21544390; DOI=10.3892/ijo.8.3.513;
RA   Pfragner R., Wirnsberger G.H., Niederle B., Behmel A., Rinner I.,
RA   Mandl A., Wawrina F., Luo J.-S., Adamiker D., Hoger H., Ingolic E.,
RA   Schauenstein K.;
RT   "Establishment of a continuous cell line from a human carcinoid of the
RT   small intestine (KRJ-I).";
RL   Int. J. Oncol. 8:513-520(1996).
RX   PubMed=22538498; DOI=10.1159/000338793;
RA   Grozinsky-Glasberg S., Shimon I., Rubinfeld H.;
RT   "The role of cell lines in the study of neuroendocrine tumors.";
RL   Neuroendocrinology 96:173-187(2012).
RX   PubMed=23119007; DOI=10.1371/journal.pone.0048411;
RA   Li S.-C., Martijn C., Cui T., Essaghir A., Luque R.M., Demoulin J.-B.,
RA   Castano J.P., Oberg K., Giandomenico V.;
RT   "The somatostatin analogue octreotide inhibits growth of small
RT   intestine neuroendocrine tumour cells.";
RL   PLoS ONE 7:E48411-E48411(2012).
RX   PubMed=29444910; DOI=10.1530/ERC-17-0445;
RA   Hofving T., Arvidsson Y., Almobarak B., Inge L., Pfragner R.,
RA   Persson M., Stenman G., Kristiansson E., Johanson V., Nilsson O.;
RT   "The neuroendocrine phenotype, genomic profile and therapeutic
RT   sensitivity of GEPNET cell lines.";
RL   Endocr. Relat. Cancer 25:367-380(2018).
RX   PubMed=31548718; DOI=10.1038/s41588-019-0490-z;
RA   Hofving T., Karlsson J., Nilsson O., Nilsson J.A.;
RT   "H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines.";
RL   Nat. Genet. 51:1426-1427(2019).
RX   PubMed=31548719; DOI=10.1038/s41588-019-0509-5;
RA   Alvarez M.J., Yan P.-R., Alpaugh M.L., Bowden M., Sicinska E.T.,
RA   Zhou C.-S.W., Karan C., Realubit R.B., Mundi P.S., Grunn A., Jager D.,
RA   Chabot J.A., Fojo A.T., Oberstein P.E., Hibshoosh H., Milsom J.W.,
RA   Kulke M.H., Loda M., Chiosis G., Reidy-Lagunes D.L., Califano A.;
RT   "Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell
RT   lines'.";
RL   Nat. Genet. 51:1427-1428(2019).